

November 9, 2023

For Immediate Release

To whom it may concern,

Company name: OSAKA SODA Co., LTD.

Securities Code: TSE Prime Market 4046

Representative: Kenshi Terada, Representative Director, Chief Executive Officer For inquiry: Toru Imamura, Executive Officer, General Manager, Administration Division

Tel: +81-(0)6-6110-1560

## Notice Concerning Difference between Consolidated Financial Results Forecast and Actual Results for the First Six Months of the Fiscal Year Ending March 31, 2024

This is to inform you that there is a difference between the consolidated financial forecast for the first six months of the fiscal year ending March 31, 2024 announced on May 11, 2023 and the actual results announced today.

1. Difference between the consolidated financial forecast and actual results for the first six months of the fiscal year ending March 31, 2024 (from April 1, 2023 to September 30, 2023)

(Millions of yen; unless otherwise noted)

	Net	Operating	Ordinary	Net Income	Earnings
	Sales	Income	Income	attributable to	per share
				owners of the	(yen)
				parent	
Previous Forecast (A)	51,000	3,600	4,100	2,800	110.06
Announced results(B)	46,622	4,917	6,020	4,042	158.91
Change (B-A)	(4,378)	1,317	1,920	1,242	-
Change (%)	(8.6)	36.6	46.8	44.4	-
(Reference) Results for					
the previous fiscal year	51,915	9,722	10,854	7,505	314.73
(first six months of the					
fiscal year ended March					
31, 2023)					



## 2.Reason for the difference

For the first six months of the consolidated fiscal year, net sales were lower than expected due to the impact of manufacturing equipment problems at the Mizushima Plant and a decline in sales volume due to a decline in domestic and overseas demand. In terms of profit, on the other hand, the yen's exchange rate was weaker than expected, prices of basic chemicals were higher than expected, and sales of healthcare products such as pharmaceutical purification materials increased steadily, exceeding expectations.

As for the full-year consolidated financial forecast, although sales of healthcare products are expected to remain steady, there are concerns that the recovery of sales will be delayed due to continued stagnation in demand as a result of the delayed economic recovery in China, etc. Therefore, we decided to maintain the figures announced on May 11, 2023.